Nanjing Vishee Medical Technology688580.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Nanjing Vishee Medical Technology (688580.SH) trades at a P/E of 22.00x, P/B of 2.20x, P/S of 8.21x, and a dividend yield of 2.79%.
Longitudinal percentile comparison: P/E sits at the 8th percentile over the trailing 10Y window (vs. 12th percentile over 3Y); P/B sits at the 19th percentile over the trailing 10Y window (vs. 36th percentile over 3Y); P/S sits at the 15th percentile over the trailing 10Y window (vs. 31st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 25th percentile within its industry and the 28th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.79%, ranking at the 82nd percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 11.0 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Nanjing Vishee Medical Technology operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 688580 · SSE: 688580 · 688580
Want the full picture on whether Nanjing Vishee Medical Technology (688580.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 22.00 | ||||||
| P/B (MRQ) | 2.20 | ||||||
| P/S (TTM) | 8.21 | ||||||
| Dividend Yield | 2.79% | ||||||
| Buyback + Div Yield | 2.79% |